(such as insurance and securities companies) that do not file financial reports with the Federal Reserve System. The Federal Reserve solicits comment on whether such a materiality test would be helpful, and, if so, how this should be defined. The FR Y–6 and FR Y–7 include organization charts, which would collect information about entities that would not be reportable on the proposed FR Y–10 and FR Y–10F. The Federal Reserve solicits comment on whether reporters would find it easier to annotate the organization charts to show the entities that are not reportable on the proposed new reports or to list those entities separately.

The proposed FR Y–10 and FR Y–10F would collect information about a reportable entity's primary activity, and the proposed definition of 'primary' is based on revenue. The Federal Reserve solicits comment on whether gross or net revenue is appropriate for this definition or, as an alternative, whether assets should be used.

The Federal Reserve also solicits comments on whether reporters would find NAICS codes useful in describing the activities of their nonbanking entities.

Board of Governors of the Federal Reserve System, September 15, 2000.

Jennifer J. Johnson,

Secretary of the Board.

[FR Doc. 00–24156 Filed 9–19–00; 8:45 am]

BILLING CODE 6210–01–P

FEDERAL RESERVE SYSTEM

Formations of, Acquisitions by, and Mergers of Bank Holding Companies

The companies listed in this notice have applied to the Board for approval, pursuant to the Bank Holding Company Act of 1956 (12 U.S.C. 1841 *et seq.*) (BHC Act), Regulation Y (12 CFR Part 225), and all other applicable statutes and regulations to become a bank holding company and/or to acquire the assets or the ownership of, control of, or the power to vote shares of a bank or bank holding company and all of the banks and nonbanking companies owned by the bank holding company, including the companies listed below.

The applications listed below, as well as other related filings required by the Board, are available for immediate inspection at the Federal Reserve Bank indicated. The application also will be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing on the standards enumerated in the BHC Act (12 U.S.C. 1842(c)). If the proposal also involves the acquisition of a nonbanking company, the review also includes whether the acquisition of the nonbanking company complies with the standards in section 4 of the BHC Act (12 U.S.C. 1843). Unless otherwise noted, nonbanking activities will be conducted throughout the United States. Additional information on all bank holding companies may be obtained from the National Information Center website at www.ffiec.gov/nic/.

Unless otherwise noted, comments regarding each of these applications must be received at the Reserve Bank indicated or the offices of the Board of Governors not later than October 16, 2000.

A. Federal Reserve Bank of Richmond (A. Linwood Gill, III, Vice President) 701 East Byrd Street, Richmond, Virginia 23261–4528:

1. BB&T Corporation, Winston-Salem, North Carolina; to merge with FCNB Corp, Frederick, Maryland, and thereby indirectly acquire FCNB Bank, Frederick, Maryland.

Board of Governors of the Federal Reserve System, September 15, 2000.

Jennifer J. Johnson,

Secretary of the Board.

[FR Doc. 00–24157 Filed 9–19–00; 8:45 am]

BILLING CODE 6210–01–P

FEDERAL RESERVE SYSTEM

Sunshine Act Meeting

AGENCY HOLDING THE MEETING: Board of Governors of the Federal Reserve System.

TIME AND DATE: 10 a.m., Monday, September 25, 2000.

PLACE: Marriner S. Eccles Federal Reserve Board Building, 20th and C Streets, NW., Washington, D.C. 20551.

STATUS: Closed.

MATTERS TO BE CONSIDERED:

1. Personnel actions (appointments, promotions, assignments, reassignments, and salary actions) involving individual Federal Reserve System employees.

2. Any items carried forward from a previously announced meeting.

CONTACT PERSON FOR MORE INFORMATION: Lynn S. Fox, Assistant to the Board; 202–452–3204.

SUPPLEMENTARY INFORMATION: You may call 202–452–3206 beginning at approximately 5 p.m. two business days before the meeting for a recorded announcement of bank and bank holding company applications scheduled for the meeting; or you may contact the Board's Web site at http://www.federalreserve.gov for an electronic announcement that not only lists applications, but also indicates procedural and other information about the meeting.

Dated: September 15, 2000.

Jennifer J. Johnson,

Secretary of the Board.

[FR Doc. 00–24193 Filed 9–15–00; 5:01 pm]

BILLING CODE 6210–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Clinical Laboratory Improvement Advisory Committee (CLIAC): Notice; Correction

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC) announces the following committee notice correction.

This notice announces the correction of previously announced meeting in the **Federal Register:** August 25, 2000 (Volume 65, Number 166) [Notices—Page 51832]

ACTION: Notice; correction.

Name: Clinical Laboratory Improvement Advisory Committee (CLIAC).

Times and Dates:

8:30 a.m.—5 p.m., September 27, 2000
8:30 a.m.—3:30 p.m., September 28, 2000

Place: CDC, Koger Center, Williams Building, Conference Rooms 1802 and 1805, 2877 Brandywine Road, Atlanta, Georgia 30341.

Status: Open to the public, limited only by the space available. The meeting room accommodates approximately 85 people.

Purpose: This committee is charged with providing scientific and technical advice and guidance to the Secretary of Health and Human Services, the Assistant Secretary for Health, and the Director, CDC, regarding the need for, and the nature of, revisions to the standards under which clinical laboratories are regulated; the impact of proposed revisions to the standards; and the modification of the standards to accommodate technological advances.

Matters to be Discussed: This agenda has been updated since previously published on August 25, 2000. The agenda will include an orientation of new members. The morning session of the first day will be devoted to the orientation which consists of providing

background information on the Clinical Laboratory Improvement Amendments of 1988 (CLIA) program. The revised agenda also will include the workgroup report on specimens and test systems not currently regulated under CLIA, the criteria and process for waiver, and updates from CDC, Food and Drug Administration and Health Care Financing Administration.

The Committee solicits oral and written testimony on specimens and test systems not currently regulated under CLIA. Requests to make an oral presentation should be submitted in writing to the contact person listed below by close of business, September 20, 2000. All requests to make oral comments should contain the name, address, telephone number, and organizational affiliation of the presenter.

Written comments should not exceed five single-spaced typed pages in length and should be received by the contact person listed below by close of business, September 20, 2000.

Agenda items are subject to change as priorities dictate.

CONTACT PERSON FOR ADDITIONAL INFORMATION: Rhonda Whalen, Acting Chief, Laboratory Practice Standards Branch, Division of Laboratory Systems, Public Health Practice Program Office, CDC, 4770 Buford Highway, NE, Mailstop F–11, Atlanta, Georgia 30341–3724, telephone 770/488–8042, fax 770/488–8279.

The Director, Management Analysis and Services Office, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities for both CDC and the Agency for Toxic Substances and Disease Registry.

Dated: September 6, 2000.

Carolyn J. Russell,

Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.

[FR Doc. 00–24106 Filed 9–19–00; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Streamlining the Blood Donor History Questionnaire; Public Workshop

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

The Food and Drug Administration (FDA) is announcing a public workshop entitled ''Streamlining the Blood Donor History Questionnaire.'' The purpose of the public workshop is to streamline the blood donor history questionnaire without compromising the safety of the nation's blood supply. The public workshop is jointly sponsored by FDA and the American Association of Blood Banks.

Date and Time: The public workshop will be held on October 16, 2000, from 8:30 a.m. to 5 p.m.

Location: The public workshop will be held at the Lister Hill Conference Center, National Institutes of Health, Building 38A, 8600 Rockville Pike, Bethesda, MD 20894.

Contact: Joseph Wilczek, Center for Biologics Evaluation and Research (HFM–350), Food and Drug Administration, 1401 Rockville Pike, Rockville, MD 20852–1448, 301–827–6129, FAX 301–827–2843.

Registration: Mail or fax your registration information (including name, title, firm name, address, telephone, and fax number) to Joseph Wilczek (address above) by Friday, October 6, 2000. There is no registration fee for the public workshop. Seating is limited, therefore interested parties are encouraged to register early. Registration at the site will be done on a space available basis on the day of the public workshop, beginning at 7:30 a.m. If you need special accommodations due to a disability, please contact Joseph Wilczek at least 7 days in advance.

Agenda: The public workshop is expected to address, but is not limited to, the following issues and topics: (1) The role of the blood donor interview in assuring blood safety; (2) overview of past efforts to improve the donor history questionnaire; (3) different methodologies in performing donor history evaluations; (4) validating the donor history questionnaire as a tool for reducing and eliminating risks to the blood supply; (5) analysis of error and accident reports and post donation information that resulted from inaccurate or misleading donor history responses; and (6) suggestions on how the donor questionnaire can be streamlined without compromising either donor, product, or recipient safety.

The public workshop agenda will be posted on the FDA Internet as soon as the information becomes available. The FDA Internet address is http://www.fda.gov/cber/whatsnew.htm.

Transcripts: Transcripts of the public workshop may be requested in writing from the Freedom of Information Office (HFI–35), Food and Drug Administration, 5600 Fishers Lane, rm. 12A–16, Rockville, MD 20857, approximately 15 working days after the meeting at a cost of 10 cents per page. The transcript will also be available on the FDA Internet site at http://www.fda.gov/cber/minutes/workshop-min.htm.

Dated: September 14, 2000.

William K. Hubbard,

Senior Associate, Commissioner for Policy, Planning, and Legislation.

[FR Doc. 00–24124 Filed 9–19–00; 8:45 am]

BILLING CODE 4160–01–F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Evaluation of New Vaccines: How Much Safety Data?; Public Workshop

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice of public workshop.

The Food and Drug Administration (FDA) is announcing the following public workshop: ''Evaluation of New Vaccines: How Much Safety Data?'' The purpose of the workshop is to address issues in the safety evaluation of new vaccines, including the feasibility and desirability of performing larger pre-licensure trials of vaccines in order to provide more precise measures of safety prior to widespread use, and to discuss the optimal balance between pre-licensure and post-licensure evaluation of vaccine safety.

Date and Time: The workshop will be held on November 14, 2000, from 1 p.m. to 5:30 p.m. and on November 15, 2000, from 8:30 a.m. to 5 p.m.

Location: The workshop will be held at the Lister Hill Conference Center, National Institutes of Health, Bldg. 38A, 8600 Rockville Pike, Bethesda, MD 20814.

Contact:

For information regarding this notice: Nathaniel L. Geary, Center for Biologics Evaluation and Research (HFM–17), Food and Drug Administration, 1401 Rockville Pike, Rockville, MD 20852–1448, 301–827–6210, FAX 301–827–1944.

For information regarding the workshop: Mary A. Foulkes, Center for Biologics Evaluation and Research (HFM–210), Food and Drug Administration, 1401 Rockville Pike, Rockville, MD 20852–1448, 301–827–3034, FAX 301–827–3529.

For registration information: Sandy L. Coffin, Center for Biologics Evaluation and Research (HFM–210), Food and Drug Administration, 1401 Rockville Pike, Rockville, MD 20852–1448, 301–